Merck

Keytruda bonanza inspires a facelift and plans to invest more than $600M in translational research
Endpoints
Thu, 06/15/17 - 09:37 am
Keytruda
Merck
R&D
LifeArc
J&J, Pfizer, Merck sit atop Fortune's 500 for pharma
BioPharma Dive
Wed, 06/14/17 - 11:58 am
JNJ
Pfizer
Merck
Fortune 500
PBMs
Merck pauses Keytruda trials, raising concerns about class
BioPharma Dive
Wed, 06/14/17 - 11:41 am
Merck
Keytruda
clinical trials
How Merck hopes to win in I/O combos: Q&A with Roy Baynes
BioPharma Dive
Wed, 06/14/17 - 11:39 am
Merck
immuno-oncology
Keytruda
Opdivo
Bristol-Myers Squibb
ADA: Merck, Pfizer notch success, but late with SGLT-2 data
BioPharma Dive
Tue, 06/13/17 - 12:15 pm
diabetes
Merck
Pfizer
SGLT2 inhibitor
Januvia
Invokana
Farxiga
Jardiance
Eli Lilly
Boehringer Ingelheim
AstraZeneca
JNJ
Merck halts enrollment on two PhIII Keytruda combo studies as outside monitors flag a worrying rate of deaths
Endpoints
Mon, 06/12/17 - 09:37 pm
Merck
Keytruda
clinical trials
Multiple Myeloma
Merck CEO: Gardasil plus pipeline equals big things ahead for vaccines
Fierce Pharma
Mon, 06/12/17 - 09:47 am
Merck
Pharma CEOs
Ken Frazier
vaccines
Gardasil
V114
Moderna Therapeutics
Merck, Pfizer trot out more support for latecomer SGLT2 candidate ertugliflozin
Fierce Pharma
Sun, 06/11/17 - 09:24 am
Merck
Pfizer
ertugliflozin
diabetes
Merck cautiously steps into the PD-(L)1/CTLA-4 checkpoint fray. But should it ‘go big or go home’ instead?
Endpoints
Fri, 06/9/17 - 11:13 am
Merck
anti-PD-L1
Keytruda
MK-1308
Bristol-Myers Squibb
Top 10 diabetes drugs by 2016 sales
Fierce Pharma
Thu, 06/8/17 - 10:04 am
diabetes
Sanofi
Novo Nordisk
Eli Lilly
Merck
Lantus
Januvia
Victoza
Levemir
Humalog
Novolog
Invokana
Why Array BioPharma Inc. Sank 13.5% in May
Motley Fool
Wed, 06/7/17 - 10:08 am
Array Biopharma
Bristol-Myers Squibb
Merck
Opdivo
Keytruda
binimetinib
encorafenib
An Unprecedented FDA Approval Bodes Well for this Drug Stock
Motley Fool
Wed, 06/7/17 - 10:05 am
Merck
FDA
Keytruda
biomarkers
solid tumors
ASCO17: Merck touts Keytruda bladder benefit post Tecentriq failure
BioPharma Dive
Mon, 06/5/17 - 12:13 pm
Merck
Keytruda
bladder cancer
Tecentriq
ASCO 2017
Merck (MRK) Up 2.3% Since Earnings Report: Can It Continue?
Yahoo/Zacks.com
Mon, 06/5/17 - 10:11 am
Merck
earnings
How Did Bristol Lose An Edge In Lung Cancer? It's No Mystery, Says New R&D Boss
Forbes
Sat, 06/3/17 - 09:28 am
Bristol-Myers Squibb
lung cancer
R&D
Opdivo
Merck
Keytruda
The immuno-oncology market prepares for the inevitable question: 'What's next?'
Medical Marketing and Media
Thu, 06/1/17 - 02:51 pm
immuno-oncology
Keytruda
Merck
Opdivo
Bristol-Myers Squibb
Merck Ventures leads $11M round in solid tumor startup
Fierce Biotech
Wed, 05/31/17 - 11:07 pm
Merck Ventures
Merck
solid tumors
Inthera Bioscience
Merck KGaA
On ASCO’s Eve, Experts Fret Over Backlash to Cancer Combo Frenzy
Xconomy
Wed, 05/31/17 - 10:59 am
ASCO 2017
cancer
Merck
Keytruda
Bristol-Myers Squibb
Opdivo
Merck's experimental Ebola vaccine poised for emergency use in Congo outbreak
Fierce Pharma
Tue, 05/30/17 - 06:19 pm
Merck
vaccines
ebola virus
Prepping for ASCO? Investor Brad Loncar offers his own breakdown of what to watch for
Endpoints
Tue, 05/30/17 - 11:48 am
ASCO
IDO inhibitors
CAR-T
PDL-1 inhibitors
Merck
Incyte
NewLink Genetics
Novartis
Juno Therapeutics
Bristol-Myers Squibb

Pages